Reducing the Risk of Dementia: Efficacy of Long-Term Treatment of Hypertension

Background and Purpose— The efficacy of treating older persons for hypertension remains controversial. Although clinical trials suggest no short-term harm, or some benefits, there are little data on the effect on cognitive function of long-term antihypertensive treatment. We evaluated the risk of dementia and cognitive decline associated with duration of antihypertensive treatment. Methods— Data are from the Honolulu Asia Aging Study on Japanese American men followed since 1965. The subjects included in this analysis were hypertensive from midlife and dementia-free in 1991 (mean age 76.7 years). In 1991, 1994 and 1997, global cognitive function was assessed with the Cognitive Abilities Screening Instrument (CASI) and dementia by a standardized examination using international criteria. The sample was grouped by treatment duration (never-treated hypertensives (NTH), <5 years, 5 to 12 years, >12 years). Normotensive subjects up to 1991 were included in the analysis as a control group. Results— For each additional year of treatment there was a reduction in the risk of incident dementia (hazard ratio [HR]=0.94, 95% CI, 0.89 to 0.99). The risk for dementia in subjects with >12 years of treatment was lower compared to NTH (HR for dementia=0.40; 95% CI, 0.22 to 0.75 and for Alzheimer disease HR=0.35; 95% CI, 0.16 to 0.78) and was similar to the normotensives. Nondemented subjects with 5 to 12 years of treatment had lower yearly CASI decline compared to NTH. Conclusions— Results suggest that in hypertensive men, the duration of the antihypertensive treatment is associated with a reduced risk for dementia and cognitive decline.

[1]  W. Jagust,et al.  Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers , 1992, Neurology.

[2]  V. Feigin,et al.  Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? , 2005, Journal of the Neurological Sciences.

[3]  Jaakko Tuomilehto,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .

[4]  J. Saczynski,et al.  The Honolulu-Asia Aging Study , 2007 .

[5]  B. Corain Alzheimer's disease : advances in clinical and basic research , 1993 .

[6]  R. Havlik,et al.  APOE-epsilon4 predicts incident AD in Japanese-American men: the honolulu-asia aging study. , 2000, Neurology.

[7]  L. Launer Demonstrating the case that AD is a vascular disease: epidemiologic evidence , 2002, Ageing Research Reviews.

[8]  I. Deary,et al.  The Effects of Antihypertensive Treatment on Cognitive Function: Results from the HOPE Study , 1996, Journal of the American Geriatrics Society.

[9]  R. Havlik,et al.  The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. , 1995, JAMA.

[10]  M. Prince,et al.  Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults , 1996, BMJ.

[11]  J. Whitworth,et al.  2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension , 2003, Journal of hypertension.

[12]  V. Hirth,et al.  Age-related bias in the management of hypertension: a national survey of physicians' opinions on hypertension in elderly adults. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  R. D'Agostino,et al.  Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. , 1993, American journal of epidemiology.

[14]  K. Jellinger,et al.  Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. , 2002, Neurology.

[15]  L. Kuller,et al.  Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. , 1993, JAMA.

[16]  J. Staessen,et al.  Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. , 2001, Archives of internal medicine.

[17]  A. Hofman,et al.  Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.

[18]  M. Prince,et al.  The treatment of hypertension in older people and its effect on cognitive function. , 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[20]  J. Tuomilehto,et al.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.

[21]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[22]  W. Applegate,et al.  Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. , 1994, Archives of internal medicine.

[23]  Neil Chapman,et al.  Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.

[24]  P. Howard Treating Isolated Systolic Hypertension in the Elderly , 1994, The Annals of pharmacotherapy.

[25]  B. Winblad,et al.  Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. , 1999, Archives of neurology.

[26]  Masahiko Hiroki,et al.  Tortuosity of the White Matter Medullary Arterioles Is Related to the Severity of Hypertension , 2002, Cerebrovascular Diseases.

[27]  A Hofman,et al.  Hypertension and cerebral white matter lesions in a prospective cohort study. , 2002, Brain : a journal of neurology.

[28]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[29]  E. Teng,et al.  The Cognitive Abilities Screening Instrument (CASI): A Practical Test for Cross-Cultural Epidemiological Studies of Dementia , 1994, International Psychogeriatrics.

[30]  D J Foley,et al.  Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. , 1996, JAMA.

[31]  R. Havlik,et al.  APOE-ε4 predicts incident AD in Japanese-American men: The Honolulu–Asia Aging Study , 2000, Neurology.

[32]  C. Bulpitt,et al.  Hypertension in the Very Elderly Trial (HYVET) , 2001, Drugs & aging.

[33]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[34]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[35]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[36]  M G Marmot,et al.  Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: introduction. , 1975, American journal of epidemiology.

[37]  J. Goodwin Embracing complexity: A consideration of hypertension in the very old. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.